Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02756416|
Recruitment Status : Unknown
Verified July 2016 by University of Nottingham.
Recruitment status was: Not yet recruiting
First Posted : April 29, 2016
Last Update Posted : July 26, 2016
|Condition or disease||Intervention/treatment||Phase|
|Reversible Cerebral Vasoconstriction Syndrome||Device: MRI brain Device: ASL-MRI brain Device: MRA brain||Not Applicable|
Reversible Cerebral Vasoconstriction Syndrome (RCVS) is a group of conditions characterised by prolonged but reversible multifocal narrowing of the cerebral arteries. It presents typically as acute severe headache, usually recurrent and thunderclap in character, with or without additional symptoms and signs. Adverse complications associated with RCVS can be devastating especially if not recognised early; depending on the degree of vasoconstriction, RCVS may be associated with cortical subarachnoid haemorrhage (in approximately 34% of patients), ischaemic infarction (6-39% of patients), or concomitant posterior reversible encephalopathy syndrome (PRES, 9-38% of patients). RCVS may also present as parenchymal brain haemorrhage in 20% of cases. The data on complications rate highlight the uncertainty about the condition and indicate need for more research to better characterise the evolution of the pathology; hence need for this study as it is prospective and longitudinal.
The hallmark of RCVS is vasoconstriction seen on vascular imaging scans and typically reverses within 3 months. Prevalence of radiological vasoconstriction seen on magnetic resonance angiography (MRA) in RCVS is reported to be between 60-90% and typically appears as diffuse segmental constriction of large and medium sized vessels lasting 4-12 weeks. The main advantage of MRA is that it can be performed without the use of a radioactive tracer, thus providing a safe method for repeat observations of vascular pathology. Imaging is often negative in first 4-5 days following the onset of headache; The mean time to detect abnormality on vascular imaging has been reported as 8 days after headache onset. RCVS symptoms usually resolves by 1 month after presentation, however the adverse complications associated with RCVS may have lasting consequences as described above. Magnetic resonance imaging (MRI) is an excellent tool for characterising brain changes during the progression and resolution of RCVS. Standard structural images can identify complications of RCVS, such as bleeding, ischaemia, and PRES.
Finally, Arterial Spin Labeling (ASL) MRI can be used to non-invasively quantify perfusion of brain tissue, providing a measure of the impact of upstream arterial vasoconstriction on local cortical regions.
Cortical perfusion has not yet been extensively studied in RCVS; at time of writing, only two case reports have been published. Rosenbloom and Singhal reported a case of RCVS induced by carotid endarterectomy following a frontal lobe ischaemic stroke. Perfusion MRI showed unilateral hypo-perfusion, mainly affecting internal watershed areas with superficial cortical regions being relatively spared. In a second study, ASL-MRI was performed on a 50-year-old man with RCVS who presented with severe recurrent headaches and neurological deficits (localising to the right hemisphere). ASL-MRI demonstrated significant hypo-perfusion in the right parieto-occipital lobe, but no infarct was seen on diffusion imaging. At 12 weeks, there was complete resolution of cerebral vasoconstriction on angiography and normal perfusion findings on ASL-MRI.
These case studies suggest that perfusion MRI can offer an additional tool to confirm and understand RCVS. ASL-MRI is a non-invasive, radiation and contrast-free technique that can be performed at multiple time points to monitor changes in perfusion over the time period of RCVS resolution and assess response to potential therapeutics.
One of the disadvantages of ASL-MRI is a low signal to noise ratio, this can be addressed by using high-field MRI at 3 Tesla (3T). In addition, 3T MRI can provide very good spatial resolution. The University of Nottingham represents one of the leading international research centres with experience in using high and ultra-high field MRI for investigating different neurological diseases such as multiple sclerosis and brain tumours with excellent results. Applying advanced non-invasive MRI techniques in this study will be a significant advantage as we investigate RCVS, understand the pathophysiology, and assess brain perfusion in multiple time points.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||May 2017|
Experimental: ASL MRI and MRA
All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
Device: MRI brain
Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
Device: ASL-MRI brain
ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
Device: MRA brain
MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
- Change in cortical cerebral blood flow (CBF) measured in ml/100g/min using ASL-MRI. [ Time Frame: Baseline, month 1, and month 3 ]The process includes detailed imaging analysis.
- Change in Circle of Willis arteries and major branches structure, this will be assessed by MRA and examined by a neuro-radiologist. [ Time Frame: Baseline, month 1, and month 3 ]Correlation between vascular changes and perfusion levels will be measured.
- RCVS complications, such as ischaemia, bleeding, and posterior reversible encephalopathy syndrome, will be assessed using standard MRI brain sequences. [ Time Frame: Baseline, month 1, and month 3 ]Correlation between occurrence of these complications and perfusion levels will be measured.
- Headache characteristics; participants will be questioned about their headache using a questionnaire as part of the case report form. [ Time Frame: Baseline, month 1, and month 3 ]Correlation between headache characteristics and perfusion levels will be measured.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02756416
|Contact: Nikos Evangelou, FRCP, D.Philemail@example.com|
|Contact: Yasser Falah, MBChB, MRCPfirstname.lastname@example.org|
|Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK||Not yet recruiting|
|Nottingham, Nottinghamshire, United Kingdom, NG7 2UH|
|Contact: Nikos Evangelou, FRCP, D.Phil 00441159709735 email@example.com|
|Contact: Yasser Falah, MBChB, MRCP 00441158231082 firstname.lastname@example.org|
|Principal Investigator: Nikos Evangelou, FRCP, D.Phil|